Replies to post #61057 on Amarantus Bioscience Holdings Inc (AMBS)

[barbershop]

Very impressive BCN.

By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed.

[barbershop]

MANF is only one side of the story for AMBS. Alzheimers is also an opportunity to create shareholder value.

Alzheimers Diagnostics Market Opportunity is Extremely Large.
The estimated cost of unpaid care in the United States is estimated at over $210 billion annually and the total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. It is estimated that these figures will double by 2050.

Amarantus believes the market opportunity for an effective Alzheimer's disease diagnostic far exceeds $500 million annually.

Tons of Potential overall with AMBS!